Beneficial effect of sodium-glucose cotransporter 2 inhibitors on kidney function can be just a mirage

doi:10.5527/wjn.v14.i4.110990

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

(38)

(56)

(0)

(12)

(1014)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Nephrol. Dec 25, 2025; 14(4): 110990
Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.110990

Full Size Figure Download Figure

Figure 2 The sodium glucose cotransporter-2 protein conveys glucose and sodium from the lumen of the kidney proximal tubule to the blood. SGLT2: Sodium-glucose cotransporter-2.

Citation: Adeva-Andany MM. Beneficial effect of sodium-glucose cotransporter 2 inhibitors on kidney function can be just a mirage. World J Nephrol 2025; 14(4): 110990
URL: https://www.wjgnet.com/2220-6124/full/v14/i4/110990.htm
DOI: https://dx.doi.org/10.5527/wjn.v14.i4.110990

Adeva-Andany MM. Beneficial effect of sodium-glucose cotransporter 2 inhibitors on kidney function can be just a mirage. World J Nephrol 2025; 14(4): 110990 [PMID: 41479824 DOI: 10.5527/wjn.v14.i4.110990]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.